Heart failure (HF) is characterized by global alterations in myocardial DNA methylation, yet little is known about epigenetic regulation of the non-coding genome and potential reversibility of DNA methylation with left ventricular assist device (LVAD) therapy. Genome-wide mapping of myocardial DNA methylation in 36 HF patients at LVAD implantation, 8 patients at LVAD explantation, and 7 non-failing donors using a high-density bead array platform identified 2079 differentially methylated positions (DMPs) in ischemic cardiomyopathy and 261 DMPs in nonischemic cardiomyopathy. LVAD support resulted in normalization of 3.2% of HF-associated DMPs. Methylation-expression correlation analysis yielded several protein-coding genes that are hypomethylated and upregulated (HTRA1, FBXO16, EFCAB13, AKAP13) or hypermethylated and downregulated (TBX3) in HF. A novel cardiac-specific super-enhancer lncRNA (LINC00881) is hypermethylated and downregulated in human HF. LINC00881 is an upstream regulator of sarcomere and calcium channel gene expression including MYH6, CACNA1C, and RYR2. LINC00881 knockdown reduces peak calcium amplitude in the beating human iPS cell derived cardiomyocytes. Collectively, these data suggest that HF-associated changes in myocardial DNA methylation within coding and non-coding genome are minimally reversible with mechanical unloading. Epigenetic reprogramming strategies may be necessary to achieve sustained clinical recovery from heart failure.